Retrospective Study
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Oct 15, 2023; 14(10): 1532-1540
Published online Oct 15, 2023. doi: 10.4239/wjd.v14.i10.1532
Effects of insulin aspart and metformin on gestational diabetes mellitus and inflammatory markers
Yan Wang, Min Song, Bang-Ruo Qi
Yan Wang, Min Song, Bang-Ruo Qi, Department of Obstetrics and Gynecology, Sanya Women and Children’s Hospital Managed by Shanghai Children’s Medical Center, Sanya 572099, Hainan Province, China
Author contributions: Wang Y and Song M contributed equally to this study. Wang Y designed the research; Song M performed the research; Wang Y and Qi BR analyzed the data and wrote the manuscript; and all authors have read and approved the final manuscript.
Institutional review board statement: The study was reviewed and approved by Sanya Women and Children’s Hospital Managed by Shanghai Children’s Medical Center.
Informed consent statement: All patients have signed informed consent forms.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: According to the institutional policy, data for this study can be obtained from the corresponding author upon request.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Bang-Ruo Qi, MD, Lecturer, Department of Obstetrics and Gynecology, Sanya Women and Children’s Hospital Managed by Shanghai Children’s Medical Center, No. 339 Yingbin Road, Jiyang District, Sanya 572099, Hainan Province, China. bangruoqi@126.com
Received: July 6, 2023
Peer-review started: July 6, 2023
First decision: July 27, 2023
Revised: August 2, 2023
Accepted: August 15, 2023
Article in press: August 15, 2023
Published online: October 15, 2023
Processing time: 95 Days and 2.4 Hours
ARTICLE HIGHLIGHTS
Research background

Gestational diabetes mellitus (GDM) is a type of hyperglycemia during pregnancy, which requires timely diagnosis, treatment and monitoring to avoid negative effects on maternal and infant health. In order to improve the therapeutic effect of patients with GDM, a new combination drug regimen has received extensive attention in the past few years.

Research motivation

The study was designed to investigate the effect of insulin aspart combined with metformin on inflammatory cytokine levels and overall improvement of patients with GDM. By studying the therapeutic effect and pharmacological mechanism of this new combination drug regimen, it can provide a reference for the precise treatment of patients with GDM, and a scientific basis for the protection of high-risk groups during pregnancy.

Research objectives

This study aimed to explore the efficacy of insulin aspart combined with metformin in treating GDM, and evaluate the effect of combined medication on lowering blood glucose level, and improving inflammatory response and metabolic disorder. The study revealed the advantages and limitations of the combined therapy regimen in clinical application, thus providing a scientific reference for future improvement of treatment strategies for GDM.

Research methods

This study was designed to retrospectively analyze 124 patients with GDM over a period of 2 years, divide them into two groups according to different treatment methods for analysis and comparison, and discuss the differences in blood-glucose-related indexes, serum-related factors, inflammatory cytokines, adverse pregnancy outcomes and pregnancy complications of patients with different treatment methods.

Research results

Insulin aspart combined with metformin can improve blood-glucose-related indexes (fasting blood glucose, 2-h postprandial glucose, glycosylated hemoglobin), serum-related factor (homocysteine) and serum inflammatory cytokines (tumor necrosis factor-α, interleukin-6, C-reactive protein) of patients, effectively reduce the incidence of adverse pregnancy outcomes and complications, and have a high level of safety.

Research conclusions

We studied the effectiveness of combined therapy for treating GDM and made breakthroughs in the treatment plan for this disease. These research achievements will help to more accurately determine the treatment plan for patients and promote the further development of the prevention and treatment of GDM and its complications.

Research perspectives

In follow-up studies, we hope to increase the sample size, extend the study duration, conduct follow-up, and explore the long-term prognosis of this combination therapy for both mothers and fetuses, thus improving our conclusions.